Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

Randomized, placebo-controlled trial finds that low-dose semaglutide reduces amount of alcohol consumption, alcohol cravings, and heavy drinking days. Reductions in cigarettes per day were also seen.

While there is currently limited data on its risks and benefits for those with type 1 diabetes, new research offers promising insights. A new study shows that semaglutide can improve glucose ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

A new clinical trial suggests that once-weekly semaglutide may reduce alcohol consumption and cravings in adults with alcohol use disorder.

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital ...

While there is currently limited data on its risks and benefits for those with type 1 diabetes, new research offers promising insights. A new study shows that semaglutide can improve glucose ...